Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis: Systematic review: management of primary sclerosing cholangitis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Primary sclerosing cholangitis (PSC) remains a challenging disease to manage. The main goals are prevention of disease progression and reduction of the increased cancer risk. AIMS: To review the management strategies for PSC and its variant forms based on published studies. METHODS: Publications were identified using Pubmed, Medline and Ovid search engines. RESULTS: Distinguishing PSC from variants, such as IgG4-associated cholangitis, and overlap with autoimmune hepatitis is essential to guide treatment decisions. There is no proven efficacious medical treatment for PSC. Ursodeoxycholic acid has been disappointing in low and moderate doses, and potentially dangerous in higher doses, although its role and optimal dose in chemoprevention requires investigation. The novel bile acid, 24-norursodeoxycholic acid, has shown promise in mouse models; human trials are in progress. Dominant strictures are optimally managed by dilatation and stenting to relieve obstructive complications, although exclusion of biliary malignancy is essential. Liver transplantation is the only proven therapy for those with advanced disease. Cholangiocarcinoma remains the most unpredictable and feared complication. In highly selected groups, neo-adjuvant chemoradiation with liver transplantation seems promising, but requires further validation. Screening for inflammatory bowel disease and surveillance for colorectal carcinoma should not be overlooked. CONCLUSIONS: The effective management of PSC and its variants is hindered by uncertainties regarding pathogenesis of disease and factors responsible for its progression. Genome studies may help to identify further targets for drug therapy and factors leading to malignant transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729 · cited 3×
“and has been discussed in detail in the recent European guidelines.(122) LIVER TRANSPLANT”
InfluentialImmunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 3×
“Gall-bladder dysplasia, adenoma and carcinoma have all been described in PSC patients, with a cumulative lifetime incidence of 2%.(91)”
InfluentialRea, D. J., Heimbach, J. K., Rosen, C. B., Haddock, M. G., Alberts, S. R., Kremers, W. K., Gores, G. J., & Nagorney, D. M. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000179678.13285.fa · Cited by 693
Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448 · cited 2×
“Early pilot studies of UDCA, in doses ranging from 10 to 15 mg ⁄ kg ⁄ day, demonstrated biochemical and in some, histological improvement.43–46 A larger double-blind placebo-controlled study of UDCA 13– 15 mg ⁄ kg ⁄ day in 105 patients with PSC showed an improvement in liver biochemistry, but no improvement in symptom…”
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394 · cited 3×
“5 years, although it was insufficiently powered to achieve statistical significance, and biochemical response was poor suggesting an issue with drug compliance.(50)”
InfluentialCharatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393 · cited 2×
“In those who are symptomatic, serum Ca19-9 levels of >130 U ⁄ mL have been reported to have a sensitivity of 79% and a specificity of 98% for presence of CCA, although this often identifies advanced 1282 Aliment Pharmacol Ther 2011; 33: 1273–1291 ª 2011 Blackwell Publishing Ltd unresectable CCA which limits its use.10…”
Bergasa, N. V., Alling, D. W., Talbot, T. L., Swain, M. G., Yurdaydin, C., Turner, M. L., Schmitt, J. M., Walker, E. C., & Jones, E. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00001 · Cited by 365
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
Mitchell, S. A., Bansi, D. S., Hunt, N., Bergmann, K. V., Fleming, K. A., & Chapman, R. W. (2001) · Gastroenterology · doi:10.1053/gast.2001.27965 · Cited by 351
Self-citationOral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339 · cited 1×
“unresectable CCA which limits its use.(105) Some clinicians screen asymptomatic patients with annual serum Ca19-9 levels and cross-sectional imaging of the hepatobiliary system, although this requires validation.”
Sertraline as a first-line treatment for cholestatic pruritus
Mayo, M. J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y., & Rush, J. A. (2007) · Hepatology · doi:10.1002/hep.21553 · Cited by 329
The natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305 · cited 20×
“A retrospective diagnosis of ‘PSC-AIH overlap syndrome’ was established in 8% of 113 PSC patients from The Netherlands and 1% of 211 PSC patients from the United States, using the modified AIH score.20, 21 Prospective analysis revealed an overlap syndrome in 17% of a cohort of 41 PSC patients from Italy, defined by a…”
InfluentialSelf-citationAlabraba, E., Nightingale, P., Gunson, B., Hubscher, S., Olliff, S., Mirza, D., & Neuberger, J. (2009) · Liver Transplantation · doi:10.1002/lt.21679 · Cited by 298 · cited 1×
“The natural history of recurrent disease is variable; about one-third with recurrence developing progressive disease over a 10-year follow-up period leading to re-transplantation or death.(173) Re-transplantation rates seem higher for patients with PSC compared with other diseases.”
Kaplan, G. G., Laupland, K. B., Butzner, D., Urbanski, S. J., & Lee, S. S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01103.x · Cited by 273 · cited 1×
“It may be the first presentation of PSC in 6% of patients.(87) Recurrent and”
Dave, M., Elmunzer, B. J., Dwamena, B. A., & Higgins, P. D. R. (2010) · Radiology · doi:10.1148/radiol.10091953 · Cited by 265
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242 · cited 2×
“Harnois et al.(179) Open label 30 25–30 mg ⁄ kg 12 Improved liver function and survival compared with Mayo risk score Okolicsanyi et al.”
Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230 · cited 2×
“5 mg ⁄ kg ⁄ day, tapered to 10–15 mg ⁄ day) and azathioprine (50–75 mg), showed a good biochemical response.(22) PSC–AIH overlap syndrome has a better prognosis than PSC, as predicted by the Mayo score, but poorer outcome than AIH.”
Sclerosing cholangitis: a focus on secondary causes
Abdalian, R., & Heathcote, J. E. (2006) · Hepatology · doi:10.1002/hep.21405 · Cited by 230 · cited 1×
“stricturing and segmental dilatation, once secondary sclerosing cholangitis and other causes of cholestasis are excluded.(4)Laboratory investigation often reveals chole-”
Selection of patients for liver transplantation and allocation of donated livers in the UK
Neuberger, J., Gimson, A., Davies, M., Akyol, M., O’Grady, J., Burroughs, A., Hudson, M., for the Liver Advisory Group, & Transplant, U. B. A. (2008) · Gut · doi:10.1136/gut.2007.131730 · Cited by 227 · cited 5×
“Systematic review: management options for primary sclerosing cholangitis and its variant forms – IgG4-associated cholangitis and overlap with autoimmune hepatitis E. L. Culver & R. W. Chapman John Radcliffe Hospital, Oxford, UK.”
InfluentialFärkkilä, M., Karvonen, A., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., & Kärkkäinen, P. (2004) · Hepatology · doi:10.1002/hep.20457 · Cited by 218 · cited 2×
“oral 12 months Significant improvement in liver biochemistry and Mayo risk score Farkkila et al.(206) Randomised controlled trial 80 Metronidazole with or without UDCA 36 months Improved serum ALP and new Mayo risk score with combination therapy.”
Small-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis
Kaya, M., Petersen, B. T., Angulo, P., Baron, T. H., Andrews, J. C., Gostout, C. J., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03690.x · Cited by 196 · cited 1×
“50% respectively).(71) Stenting is therefore usually reserved for strictures that are refractory to dilatation.”
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant
Buckles, D. C., Lindor, K. D., LaRusso, N. F., Petrovic, L. M., & Gores, G. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05677.x · Cited by 194
Gallbladder disease in patients with primary sclerosing cholangitis
Said, K., Glaumann, H., & Bergquist, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.019 · Cited by 193
Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis
Datta, D. V., & Sherlock, S. (1966) · Gastroenterology · doi:10.1016/s0016-5085(66)80071-9 · Cited by 181
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
Ursodeoxycholic acid for primary sclerosing cholangitis
Chazouillères, O., Poupon, R., Capron, J.-P., Metman, E.-H., Dhumeaux, D., Amouretti, M., Couzigou, P., Labayle, D., & Trinchet, J.-C. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90281-u · Cited by 165 · cited 2×
“Chazouillères et al.(44) Prospective 15 750–1250 mg 6 Improved liver function and symptoms”
Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162
Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis
Boberg, K. M., Jebsen, P., Clausen, O. P., Foss, A., Aabakken, L., & Schrumpf, E. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.010 · Cited by 159
Lundqvist, K., & Broomé, U. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02258391 · Cited by 159
Rudolph, G., Gotthardt, D., Klöters-Plachky, P., Kulaksiz, H., Rost, D., & Stiehl, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.023 · Cited by 156 · cited 1×
“reduced survival in one prospective nonrandomised study, if stenoses were opened endoscopically and infection was adequately treated with antibiotics.(67) Patients with recur-”
Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis
Bangarulingam, S. Y., Gossard, A. A., Petersen, B. T., Ott, B. J., & Lindor, K. D. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.161 · Cited by 152
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis
Wiesner, R. H., LaRusso, N. F., Dozois, R. R., & Beaver, S. J. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90926-1 · Cited by 148 · cited 1×
“peristomal varicies, which can bleed recurrently and be difficult to manage.(148) Local treatments with injection of”
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisNote
van Buuren, H. R., van Hoogstraten, H. J. F., Terkivatan, T., Schalm, S. W., & Vleggaar, F. P. (2000) · Journal of Hepatology · doi:10.1034/j.1600-0641.2000.033004543.x · Cited by 143
Cullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136 · cited 3×
“No effect on symptoms Cullen et al.51 Pilot dose range study 30 10 mg ⁄ kg 20 mg ⁄ kg 30 mg ⁄ kg 24 Improved projected survival with low and standard dose.”
InfluentialSelf-citationBroomé, U., Glaumann, H., Lindstöm, E., Lööf, L., Almer, S., Prytz, H., Sandberg-Gertzén, H., Lindgren, S., Fork, F.-T., Järnerot, G., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00036-3 · Cited by 131
JONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114
Pohl, J., Ring, A., Stremmel, W., & Stiehl, A. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200601000-00012 · Cited by 111 · cited 1×
“icate bacteria in the context of an obstructed system; therapeutic drainage in addition is considered more effective.(88)”
Abraham, S. C., Kamath, P. S., Eghtesad, B., Demetris, A. J., & Krasinskas, A. M. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213286.65907.ea · Cited by 72 · cited 1×
“In PSC patients with refractory severe bacterial cholangitis, but otherwise preserved liver function, transplantation may be indicated.(90)”
Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment
Parés, A., & Guañabens, N. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.005 · Cited by 63
Cited by
Lindström, L., Hultcrantz, R., Boberg, K. M., Friis–Liby, I., & Bergquist, A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.032 · Cited by 180
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis
Triantos, C. K., Koukias, N. M., Nikolopoulou, V. N., & Burroughs, A. K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04822.x · Cited by 132
“giographic findings, but carries a completely different prognosis which is rare.(6) However, randomisation is likely to have balanced out this potential bias.”
BackgroundPrimary sclerosing cholangitis: diagnosis, prognosis, and management
Singh, S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.016 · Cited by 119
Fevery, J., Van Steenbergen, W., Van Pelt, J., Laleman, W., Hoffman, I., Geboes, K., Vermeire, S., & Nevens, F. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13516 · Cited by 61
Metadata
- Authors
- Culver, E. L., & Chapman, R. W.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-04-18
- Volume
- 33
- Issue
- 12
- Pages
- 1273-1291
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1571158377
- Cited by
- 56
- References
- 49
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.